呼吸器診断薬市場：製品タイプ、適応症、エンドユーザー別- 世界予測2024-2030年

呼吸器診断薬市場規模は2023年に61億2,000万米ドルと推計され、2024年には66億6,000万米ドルに達し、CAGR 8.67％で2030年には109億6,000万米ドルに達すると予測されています。

呼吸器診断薬は、喘息、慢性閉塞性肺疾患（COPD）、肺腫瘍、結核、肺炎などを含む呼吸器疾患の特定、モニタリング、治療に重点を置くヘルスケア産業の重要な構成要素です。呼吸器診断薬検査法には、画像検査、スパイロメトリー、ピークフロー検査、血液ガス検査、肺機能検査、その他複数の診断技術が含まれます。大気汚染レベルの上昇、喫煙、遺伝的素因、職業上の危険による呼吸器疾患の有病率の上昇により、呼吸器診断薬ソリューションの使用が必要となっています。しかし、不十分な償還や保険政策、複雑な診断手順に伴うエラーのリスクも、呼吸器診断薬の普及を妨げる可能性があります。さらに、高度な診断システムの操作には訓練を受けた専門家が必要であり、市場拡大の課題となっています。しかし、医療インフラや呼吸器健康ソリューションへのアクセス強化を目指す政府の取り組みや、研究開発活動への投資の増加は、呼吸器診断薬ソリューションの財政的・技術的制約を克服するのに役立つ可能性があります。携帯型監視装置、高度な分子診断検査、呼吸器ケアに遠隔医療サービスを取り入れることにつながるデジタル化の進展などの革新は、新たな成長分野を提供します。

製品病原体の迅速な検出ニーズがアッセイと試薬の採用を促進

呼吸器診断機器・装置は、肺や呼吸器疾患の特定に役立つ様々な検査を実施するために特別に設計されています。これには、スパイロメーター、ネブライザー、ピークフローメーター、オシロメーター、睡眠ポリグラフ、ガス分析器、睡眠検査装置などが含まれます。呼吸器診断薬で使用される試薬には、緩衝液、対照液、校正液、ヌクレオチド、DNAポリメラーゼなどの酵素、プライマー、プローブ、色素、サンプル調製用の反応液などがあります。逆転写酵素ポリメラーゼ連鎖反応（RT-PCR）、酵素結合免疫吸着測定法（ELISA）、迅速診断試験（RDT）を含むアッセイは、呼吸器病原体に関連する抗体や抗原の検出に頻繁に利用されます。ソフトウェアとサービスは、患者の健康記録の管理、データ分析、異なるヘルスケア機関間の接続を促進する上で極めて重要な役割を果たしています。電子カルテ（EHR）や病院情報システム（HIS）などのソフトウェア・ソリューションとサービスは、合理的なデータ管理と効率的な診断結果の伝達を提供します。サービスには、専門家によるコンサルテーション、機器の導入、ユーザートレーニング、定期的な診断機器のメンテナンスが含まれます。

検査の種類分子診断検査の精度と特異性を高めるための調査イニシアティブ

画像検査は、呼吸器系の構造を可視化し、異常の診断を助け、疾患の進行をモニタリングする上で重要な役割を果たしています。コンピュータ断層撮影（CT）などの画像検査は、肺のより詳細な断面図を提供し、結節、腫瘍、複雑な肺疾患を強調します。一方、磁気共鳴画像法（MRI）は、胸壁、縦隔、時には軟部組織の異常の詳細な画像診断に有用です。機械的検査は肺の物理的機能を評価します。肺機能検査（PFT）は肺活量、肺活量、流速、ガス交換を測定し、スパイロメトリーは吸ったり吐いたりできる空気の速度と量を測定することで肺の機能を評価します。分子診断学では、バイオマーカーを分子レベルで分析し、遺伝的素因、感染性病原体、疾患の特異的特徴に関する情報を提供し、精密医療を可能にします。ポリメラーゼ連鎖反応（PCR）は、呼吸器疾患における細菌やウイルスの病原体や感染の有無を検出するために用いられます。閉塞性睡眠時無呼吸症候群（OSA）検査は、睡眠中の呼吸が浅い、または停止している期間の評価に不可欠です。従来の呼吸器診断薬には、顕微鏡検査や生化学検査などの基本的な臨床検査が含まれます。結核の症例検出においては、顕微鏡検査は、その安価さ、迅速さ、手順の簡便さ、特異性の高さから、不可欠な診断ツールであり続けています。

適応慢性閉塞性肺疾患の正確な検査を達成するための高度な呼吸器診断技術の必要性

喘息は、気道の頻繁で基礎的な炎症による呼吸困難を特徴とする慢性疾患です。喘息の呼吸器診断戦略には通常、気道閉塞の程度と可逆性を評価するスパイロメトリーなどの肺機能検査が含まれます。さらに、呼気一酸化窒素（FeNO）の測定は、気道の炎症を間接的に反映し、診断にさらなる洞察を与えます。慢性閉塞性肺疾患（COPD）は呼吸困難を引き起こす進行性の肺疾患で、慢性気管支炎と肺気腫を特徴とします。COPDの呼吸器診断薬には、肺機能を測定するスパイロメトリー検査、肺を観察する胸部X線検査やCT検査、肺が血液中に酸素をどれだけ送り、二酸化炭素をどれだけ除去しているかを測定する動脈血ガス分析など、さまざまな検査が含まれます。肺がんは重篤で致死的な疾患であり、多くの場合、気管支や細気管支を覆う細胞から発生します。診断には通常、胸部X線検査やCTスキャンなどの画像検査が行われます。肺炎は、片方または両方の肺の気嚢が炎症を起こす感染症です。この病気は通常、身体検査によって診断され、その後、胸部X線検査によって感染が確認され、その部位と範囲が特定されます。さらに、喀痰検査や血液検査によって、感染の原因となっている微生物の種類を特定し、最も効果的な治療法を決定することができます。結核は、主に肺に影響を及ぼす重篤な感染症である可能性があります。結核の呼吸器診断薬では、結核への曝露を特定する皮膚テストと、活動性または潜伏性の感染を確認できるインターフェロン-γ放出アッセイの2つの主要な検査が行われます。胸部X線検査やCTスキャンは肺の損傷をさらに評価するために使用され、喀痰検査は結核菌が薬剤耐性であるかどうかを明らかにし、治療計画に役立ちます。

エンドユーザー：呼吸器疾患の特定とモニタリングのための病院や診療所における多様な診断ツールの採用

診断検査室は、呼吸器診断薬のエンドユーズにおける重要な構成要素です。これらの機関は、慢性閉塞性肺疾患（COPD）、喘息、結核、肺炎など様々な呼吸器疾患の検査や診断に一貫して携わっています。高度に進歩した複雑な検査機器を備えた診断検査室は、正確で信頼性の高い結果を提供し、適切な治療と回復に向けたペイシェントジャーニーの重要な一里塚となります。ヘルスケア提供における主要な役割を担う病院は、呼吸器疾患を特定するための最先端の呼吸器診断薬ツールを備えています。その使用範囲は外来から集中治療室まで及び、幅広い患者に正確でタイムリーな診断をもたらしています。研究機関は、呼吸器診断薬の分野で不可欠な役割を果たしています。これらの研究機関は、既存の診断ツールの有効性を評価し、次世代の呼吸器診断ソリューションを開発する上で不可欠です。これらの研究機関は、生存率を高め、患者のQOLへの影響を最小限に抑えるために、より早い段階で疾患を特定できる診断方法に関する広範な研究を促進しています。

地域別インサイト

南北アメリカは呼吸器診断薬の世界市場において重要な位置を占めています。呼吸器疾患の高い発生率と意識の高まり、積極的な医療介入が、南北アメリカにおける高度な呼吸器診断薬の必要性を高めています。洗練されたヘルスケアインフラが整っていることも、高品質な診断機器の生産を促進しています。診断サービスに対する需要の高まりと急速に発展するヘルスケアインフラの存在が、アジアにおける呼吸器診断機器の生産を支えています。呼吸器疾患の流行と国内外の主な市場プレイヤーの進出が、同地域の市場開拓を後押ししています。欧州の呼吸器診断薬市場は、革新的な呼吸器診断検査が数多く提供され、ヘルスケアシステムが確立されていることに大きな影響を受けています。欧州連合（EU）が定めた規制ガイドラインも、呼吸器診断機器の製造における厳格な品質管理に道を開いています。中東・アフリカでも呼吸器疾患の有病率が増加しており、高度な診断ソリューションの安定的な供給が求められています。同地域では地元メーカーが少ないため、呼吸器診断装置の生産は限られています。しかし、様々な国際企業がこの地域の呼吸器診断機器製造に注力し、足場を固めています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは呼吸器診断薬市場の評価において極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、呼吸器診断薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力について徹底的な評価を行います。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.呼吸器診断薬市場の市場規模および予測は？

2.呼吸器診断薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.呼吸器診断薬市場の技術動向と規制枠組みは？

4.呼吸器診断薬市場における主要ベンダーの市場シェアは？

5.呼吸器診断薬市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性呼吸器疾患に罹患しやすい高齢化人口の増加
    • 呼吸器疾患診断キット、検査、システムの承認の増加
    • 遠隔および在宅ケア検査機器の好感度が上昇
  • 抑制要因
    • 償還制限のある呼吸器診断パネルおよびキットの製品回収事例
  • 機会
    • 高度な呼吸器診断ツールを導入するための技術の進歩
    • 呼吸器診断ツールに対する政府の取り組みと資金提供
  • 課題
    • 複雑な診断手順に伴うエラーのリスク
• 市場セグメンテーション分析
  • 製品：病原体の迅速な検出の必要性が検査と試薬の採用を促進
  • 検査の種類：分子診断検査の精度と特異性を向上させるための調査イニシアチブ
  • 適応症：慢性閉塞性肺疾患の正確な検査を達成するための高度な呼吸器診断技術の必要性
  • エンドユーザー：呼吸器疾患の特定とモニタリングのための病院や診療所での多様な診断ツールの採用
• 市場動向分析
  • 南北アメリカ地域におけるヘルスケアインフラへの投資と支援的な規制状況により、市場は大きく成長する可能性があります。
  • アジア太平洋地域では、ウイルス性呼吸器感染症の監視と管理のための早期検出と呼吸器診断ソリューションが大量に必要とされています。
  • EMEA全域で確立された呼吸器診断薬開発により、政府および民間の疾病スクリーニング活動に高度な検査機能を提供できます。
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制枠組みの分析

第6章 呼吸器診断薬市場：製品別

• アッセイと試薬
• 機器とデバイス
• ソフトウェアとサービス

第7章 呼吸器診断薬市場テストタイプ別

• 画像検査
• 機械試験
• 分子診断検査
• OSA診断テスト
• 従来の診断テスト

第8章 呼吸器診断薬市場適応症別

• 喘息
• 慢性閉塞性肺疾患
• 肺がん
• 肺炎
• 結核

第9章 呼吸器診断薬市場：エンドユーザー別

• 診断検査室
• 病院・クリニック
• 調査機関

第10章 南北アメリカの呼吸器診断薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の呼吸器診断薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの呼吸器診断薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス、2023
• 競合シナリオ分析
  • NYUランゴーンヘルスがフィリップスと8年間の提携を締結
  • マシモ、ORiのFDAによる新規承認を取得
  • bioMerieuxがBIOFIRE SPOTFIRE呼吸器/咽喉炎（R/ST）パネルについてFDAに510（k）とCLIA免除の二重申請を提出
  • BD、 COVID-19、インフルエンザA/B、RSウイルス分子複合検査の510（k）承認を取得
  • ResMedが睡眠および呼吸器診断薬ソフトウェアメーカーSomnowareを買収
  • シージェン、30種類の診断検査でIVDR認証を取得
  • ホロジック、パンサーフュージョンSARS-CoV-2/インフルエンザA/B/RSVアッセイのFDA承認を発表
  • QIAGEN、症候群検査用呼吸器パネルを搭載したQIAstat-Dxを日本で発売
  • サーモフィッシャーはALPCO-GeneProofと提携し、CE-IVD分子アッセイポートフォリオを拡大
  • Molbio Diagnosticsが呼吸器疾患ポートフォリオにTruenat H3N2/H1N1検査を追加
  • Vitalographが新しい呼吸器VitaloPFTシリーズを発売
  • SDバイオセンサーとSJLパートナーズがメリディアンバイオサイエンス買収取引を完了
  • フィリップスとマシモが提携を拡大し、世界中の患者と医師の遠隔医療を向上

第14章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. RESPIRATORY DIAGNOSTICS MARKET RESEARCH PROCESS
• FIGURE 2. RESPIRATORY DIAGNOSTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. RESPIRATORY DIAGNOSTICS MARKET DYNAMICS
• FIGURE 7. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 14. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. AMERICAS RESPIRATORY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 16. AMERICAS RESPIRATORY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. UNITED STATES RESPIRATORY DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 18. UNITED STATES RESPIRATORY DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. ASIA-PACIFIC RESPIRATORY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. ASIA-PACIFIC RESPIRATORY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 23. RESPIRATORY DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 24. RESPIRATORY DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. RESPIRATORY DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY ASSAYS & REAGENTS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY ASSAYS & REAGENTS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS & DEVICES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS & DEVICES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY X-RAY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY X-RAY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MECHANICAL TESTS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MECHANICAL TESTS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MECHANICAL TESTS, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MECHANICAL TESTS, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY PEAK FLOW TEST, BY REGION, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY PEAK FLOW TEST, BY REGION, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY PULMONARY FUNCTION TESTS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY PULMONARY FUNCTION TESTS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 37. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY SPIROMETRY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 38. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY SPIROMETRY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 39. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC TESTS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 40. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC TESTS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 41. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 42. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 43. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 44. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 45. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 46. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 47. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MICROARRAYS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 48. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MICROARRAYS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 49. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, BY REGION, 2018-2023 (USD MILLION)
• TABLE 50. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, BY REGION, 2024-2030 (USD MILLION)
• TABLE 51. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2023 (USD MILLION)
• TABLE 52. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2024-2030 (USD MILLION)
• TABLE 53. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY OSA DIAGNOSTIC TESTS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 54. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY OSA DIAGNOSTIC TESTS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 55. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TESTS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 56. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TESTS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 57. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 58. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 59. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY BIOCHEMICAL TESTS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 60. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY BIOCHEMICAL TESTS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 61. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY IMMUNODIAGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 62. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY IMMUNODIAGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 63. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MICROSCOPY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 64. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MICROSCOPY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 65. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 66. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 67. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY ASTHMA, BY REGION, 2018-2023 (USD MILLION)
• TABLE 68. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY ASTHMA, BY REGION, 2024-2030 (USD MILLION)
• TABLE 69. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 70. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 71. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 72. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 73. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY PNEUMONIA, BY REGION, 2018-2023 (USD MILLION)
• TABLE 74. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY PNEUMONIA, BY REGION, 2024-2030 (USD MILLION)
• TABLE 75. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TUBERCULOSIS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 76. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TUBERCULOSIS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 77. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 78. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 79. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 80. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 81. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 82. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 83. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 84. GLOBAL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 85. AMERICAS RESPIRATORY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 86. AMERICAS RESPIRATORY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 87. AMERICAS RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
• TABLE 88. AMERICAS RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
• TABLE 89. AMERICAS RESPIRATORY DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2023 (USD MILLION)
• TABLE 90. AMERICAS RESPIRATORY DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2024-2030 (USD MILLION)
• TABLE 91. AMERICAS RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MECHANICAL TESTS, 2018-2023 (USD MILLION)
• TABLE 92. AMERICAS RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MECHANICAL TESTS, 2024-2030 (USD MILLION)
• TABLE 93. AMERICAS RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 94. AMERICAS RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 95. AMERICAS RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 96. AMERICAS RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 97. AMERICAS RESPIRATORY DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 98. AMERICAS RESPIRATORY DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 99. AMERICAS RESPIRATORY DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 100. AMERICAS RESPIRATORY DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 101. AMERICAS RESPIRATORY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 102. AMERICAS RESPIRATORY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 103. ARGENTINA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 104. ARGENTINA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 105. ARGENTINA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
• TABLE 106. ARGENTINA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
• TABLE 107. ARGENTINA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2023 (USD MILLION)
• TABLE 108. ARGENTINA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2024-2030 (USD MILLION)
• TABLE 109. ARGENTINA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MECHANICAL TESTS, 2018-2023 (USD MILLION)
• TABLE 110. ARGENTINA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MECHANICAL TESTS, 2024-2030 (USD MILLION)
• TABLE 111. ARGENTINA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 112. ARGENTINA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 113. ARGENTINA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 114. ARGENTINA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 115. ARGENTINA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 116. ARGENTINA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 117. ARGENTINA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 118. ARGENTINA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 119. BRAZIL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 120. BRAZIL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 121. BRAZIL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
• TABLE 122. BRAZIL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
• TABLE 123. BRAZIL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2023 (USD MILLION)
• TABLE 124. BRAZIL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2024-2030 (USD MILLION)
• TABLE 125. BRAZIL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MECHANICAL TESTS, 2018-2023 (USD MILLION)
• TABLE 126. BRAZIL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MECHANICAL TESTS, 2024-2030 (USD MILLION)
• TABLE 127. BRAZIL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 128. BRAZIL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 129. BRAZIL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 130. BRAZIL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 131. BRAZIL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 132. BRAZIL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 133. BRAZIL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 134. BRAZIL RESPIRATORY DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 135. CANADA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 136. CANADA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 137. CANADA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
• TABLE 138. CANADA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
• TABLE 139. CANADA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2023 (USD MILLION)
• TABLE 140. CANADA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2024-2030 (USD MILLION)
• TABLE 141. CANADA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MECHANICAL TESTS, 2018-2023 (USD MILLION)
• TABLE 142. CANADA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MECHANICAL TESTS, 2024-2030 (USD MILLION)
• TABLE 143. CANADA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 144. CANADA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 145. CANADA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 146. CANADA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 147. CANADA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 148. CANADA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 149. CANADA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 150. CANADA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 151. MEXICO RESPIRATORY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 152. MEXICO RESPIRATORY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 153. MEXICO RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
• TABLE 154. MEXICO RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
• TABLE 155. MEXICO RESPIRATORY DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2023 (USD MILLION)
• TABLE 156. MEXICO RESPIRATORY DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2024-2030 (USD MILLION)
• TABLE 157. MEXICO RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MECHANICAL TESTS, 2018-2023 (USD MILLION)
• TABLE 158. MEXICO RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MECHANICAL TESTS, 2024-2030 (USD MILLION)
• TABLE 159. MEXICO RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 160. MEXICO RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 161. MEXICO RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 162. MEXICO RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 163. MEXICO RESPIRATORY DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 164. MEXICO RESPIRATORY DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 165. MEXICO RESPIRATORY DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 166. MEXICO RESPIRATORY DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 167. UNITED STATES RESPIRATORY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 168. UNITED STATES RESPIRATORY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 169. UNITED STATES RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
• TABLE 170. UNITED STATES RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
• TABLE 171. UNITED STATES RESPIRATORY DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2023 (USD MILLION)
• TABLE 172. UNITED STATES RESPIRATORY DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2024-2030 (USD MILLION)
• TABLE 173. UNITED STATES RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MECHANICAL TESTS, 2018-2023 (USD MILLION)
• TABLE 174. UNITED STATES RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MECHANICAL TESTS, 2024-2030 (USD MILLION)
• TABLE 175. UNITED STATES RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 176. UNITED STATES RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 177. UNITED STATES RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 178. UNITED STATES RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 179. UNITED STATES RESPIRATORY DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 180. UNITED STATES RESPIRATORY DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 181. UNITED STATES RESPIRATORY DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 182. UNITED STATES RESPIRATORY DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 183. UNITED STATES RESPIRATORY DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 184. UNITED STATES RESPIRATORY DIAGNOSTICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 185. ASIA-PACIFIC RESPIRATORY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 186. ASIA-PACIFIC RESPIRATORY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 187. ASIA-PACIFIC RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
• TABLE 188. ASIA-PACIFIC RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
• TABLE 189. ASIA-PACIFIC RESPIRATORY DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2023 (USD MILLION)
• TABLE 190. ASIA-PACIFIC RESPIRATORY DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2024-2030 (USD MILLION)
• TABLE 191. ASIA-PACIFIC RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MECHANICAL TESTS, 2018-2023 (USD MILLION)
• TABLE 192. ASIA-PACIFIC RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MECHANICAL TESTS, 2024-2030 (USD MILLION)
• TABLE 193. ASIA-PACIFIC RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 194. ASIA-PACIFIC RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 195. ASIA-PACIFIC RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 196. ASIA-PACIFIC RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 197. ASIA-PACIFIC RESPIRATORY DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 198. ASIA-PACIFIC RESPIRATORY DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 199. ASIA-PACIFIC RESPIRATORY DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 200. ASIA-PACIFIC RESPIRATORY DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 201. ASIA-PACIFIC RESPIRATORY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 202. ASIA-PACIFIC RESPIRATORY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 203. AUSTRALIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 204. AUSTRALIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 205. AUSTRALIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
• TABLE 206. AUSTRALIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
• TABLE 207. AUSTRALIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2023 (USD MILLION)
• TABLE 208. AUSTRALIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2024-2030 (USD MILLION)
• TABLE 209. AUSTRALIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MECHANICAL TESTS, 2018-2023 (USD MILLION)
• TABLE 210. AUSTRALIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MECHANICAL TESTS, 2024-2030 (USD MILLION)
• TABLE 211. AUSTRALIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 212. AUSTRALIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 213. AUSTRALIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 214. AUSTRALIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 215. AUSTRALIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 216. AUSTRALIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 217. AUSTRALIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 218. AUSTRALIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 219. CHINA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 220. CHINA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 221. CHINA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
• TABLE 222. CHINA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
• TABLE 223. CHINA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2023 (USD MILLION)
• TABLE 224. CHINA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2024-2030 (USD MILLION)
• TABLE 225. CHINA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MECHANICAL TESTS, 2018-2023 (USD MILLION)
• TABLE 226. CHINA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MECHANICAL TESTS, 2024-2030 (USD MILLION)
• TABLE 227. CHINA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 228. CHINA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 229. CHINA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 230. CHINA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 231. CHINA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 232. CHINA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 233. CHINA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 234. CHINA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 235. INDIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 236. INDIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 237. INDIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
• TABLE 238. INDIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
• TABLE 239. INDIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2023 (USD MILLION)
• TABLE 240. INDIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2024-2030 (USD MILLION)
• TABLE 241. INDIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MECHANICAL TESTS, 2018-2023 (USD MILLION)
• TABLE 242. INDIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MECHANICAL TESTS, 2024-2030 (USD MILLION)
• TABLE 243. INDIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 244. INDIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 245. INDIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 246. INDIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 247. INDIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 248. INDIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 249. INDIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 250. INDIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 251. INDONESIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 252. INDONESIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 253. INDONESIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
• TABLE 254. INDONESIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
• TABLE 255. INDONESIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2023 (USD MILLION)
• TABLE 256. INDONESIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2024-2030 (USD MILLION)
• TABLE 257. INDONESIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MECHANICAL TESTS, 2018-2023 (USD MILLION)
• TABLE 258. INDONESIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MECHANICAL TESTS, 2024-2030 (USD MILLION)
• TABLE 259. INDONESIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 260. INDONESIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 261. INDONESIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 262. INDONESIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 263. INDONESIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 264. INDONESIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 265. INDONESIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 266. INDONESIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 267. JAPAN RESPIRATORY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 268. JAPAN RESPIRATORY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 269. JAPAN RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
• TABLE 270. JAPAN RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
• TABLE 271. JAPAN RESPIRATORY DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2023 (USD MILLION)
• TABLE 272. JAPAN RESPIRATORY DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2024-2030 (USD MILLION)
• TABLE 273. JAPAN RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MECHANICAL TESTS, 2018-2023 (USD MILLION)
• TABLE 274. JAPAN RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MECHANICAL TESTS, 2024-2030 (USD MILLION)
• TABLE 275. JAPAN RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 276. JAPAN RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 277. JAPAN RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 278. JAPAN RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 279. JAPAN RESPIRATORY DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 280. JAPAN RESPIRATORY DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 281. JAPAN RESPIRATORY DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 282. JAPAN RESPIRATORY DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 283. MALAYSIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 284. MALAYSIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 285. MALAYSIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
• TABLE 286. MALAYSIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
• TABLE 287. MALAYSIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2023 (USD MILLION)
• TABLE 288. MALAYSIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2024-2030 (USD MILLION)
• TABLE 289. MALAYSIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MECHANICAL TESTS, 2018-2023 (USD MILLION)
• TABLE 290. MALAYSIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MECHANICAL TESTS, 2024-2030 (USD MILLION)
• TABLE 291. MALAYSIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 292. MALAYSIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 293. MALAYSIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 294. MALAYSIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 295. MALAYSIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 296. MALAYSIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 297. MALAYSIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 298. MALAYSIA RESPIRATORY DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 299. PHILIPPINES RESPIRATORY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 300. PHILIPPINES RESPIRATORY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 301. PHILIPPINES RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
• TABLE 302. PHILIPPINES RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
• TABLE 303. PHILIPPINES RESPIRATORY DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2023 (USD MILLION)
• TABLE 304. PHILIPPINES RESPIRATORY DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2024-2030 (USD MILLION)
• TABLE 305. PHILIPPINES RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MECHANICAL TESTS, 2018-2023 (USD MILLION)
• TABLE 306. PHILIPPINES RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MECHANICAL TESTS, 2024-2030 (USD MILLION)
• TABLE 307. PHILIPPINES RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 308. PHILIPPINES RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 309. PHILIPPINES RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 310. PHILIPPINES RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 311. PHILIPPINES RESPIRATORY DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 312. PHILIPPINES RESPIRATORY DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 313. PHILIPPINES RESPIRATORY DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 314. PHILIPPINES RESPIRATORY DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 315. SINGAPORE RESPIRATORY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 316. SINGAPORE RESPIRATORY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 317. SINGAPORE RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2023 (USD MILLION)
• TABLE 318. SINGAPORE RESPIRATORY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024-2030 (USD MILLION)
• TABLE 319. SINGAPORE RESPIRATORY DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2023 (USD MILLION)
• TABLE 320. SINGAPORE RESPIRATORY DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2024-2030 (USD MILLION)
• TABLE 321. SINGAPORE RESPIRATORY DIAGNOSTICS MARKET SIZE, BY MECHANICAL TESTS, 2018-2023 (USD MILLION)

[194 Pages Report] The Respiratory Diagnostics Market size was estimated at USD 6.12 billion in 2023 and expected to reach USD 6.66 billion in 2024, at a CAGR 8.67% to reach USD 10.96 billion by 2030.

Respiratory diagnostics is a vital component of the healthcare industry, focusing on the identification, monitoring, and treatment of respiratory diseases, which include asthma, chronic obstructive pulmonary disease (COPD), lung tumors, tuberculosis, and pneumonia, among others. Respiratory diagnostics testing methods encompass the use of imaging tests, spirometry, peak flow tests, blood gas tests, pulmonary function tests, and multiple other diagnostic techniques. Escalation in the prevalence of such respiratory conditions due to rising air pollution levels, smoking, genetic predispositions, and occupational hazards has necessitated the use of respiratory diagnostics solutions. However, inadequate reimbursement and insurance policies and the risk of errors associated with complex diagnostic procedures could also impede the proliferation of respiratory diagnostics. Moreover, the need for trained professionals to operate advanced diagnostic systems presents a challenge to the market's expansion. However, government initiatives aimed at enhancing health infrastructure and access to respiratory health solutions and increasing investments in research and development activities can help overcome the financial and technical limitations of respiratory diagnostics solutions. Innovations such as portable monitoring devices, advanced molecular diagnostic tests, and increased digitalization leading to the incorporation of telehealth services in respiratory care offer new areas for growth.

Product: Need for rapid detection of pathogens driving the adoption of assays and reagents

Respiratory diagnostic instruments and devices are specifically designed to perform various tests that help identify lung and respiratory disorders. These include spirometers, nebulizers, peak flow meters, oscillometers, polysomnographs, gas analyzers, and sleep test devices. Reagents employed in respiratory diagnostics include buffers, control solutions, calibration solutions, nucleotides, enzymes such as DNA polymerases, primers, probes, dyes, and reactants for sample preparation. Assays, including the reverse transcriptase polymerase chain reaction (RT-PCR), enzyme-linked immunosorbent assay (ELISA), and rapid diagnostic tests (RDTs), are frequently utilized for the detection of antibodies or antigens related to respiratory pathogens. Software and services play a pivotal role in managing patient health records, data analysis, and facilitating connections between different healthcare entities. Software solutions and services, such as electronic health records (EHRs) and hospital information systems (HIS), offer streamlined data management and efficient diagnostic results communication. Services include professional consultation, device implementation, user training, and regular diagnostics device maintenance.

Test Type: Research initiatives to advance the accuracy and specificity of molecular diagnostic tests

Imaging tests play a critical role in visualizing the structure of the respiratory system, aiding in the diagnosis of abnormalities, and monitoring disease progression. Imaging tests such as computed tomography (CT) provide a more detailed cross-sectional view of the lungs, highlighting nodules, tumors, and complex lung diseases, while magnetic resonance imaging (MRI) is useful in detailed imaging of the chest wall, mediastinum, and occasionally soft tissue abnormalities. Mechanical tests evaluate the physical function of the lungs. Pulmonary function tests (PFTs) measure lung volume, capacity, rates of flow, and gas exchange, while spirometry assesses how well the lungs function by measuring the speed and volume of air that can be inhaled or exhaled. Molecular diagnostics involve analyzing biomarkers at the molecular level, providing information on genetic predispositions, infectious pathogens, and specific characteristics of diseases, enabling precision medicine. Polymerase chain reaction (PCR) is used to detect the presence of bacterial and viral pathogens or infections in respiratory illnesses. Obstructive sleep apnea (OSA) tests are vital in assessing periods of shallow or paused breathing during sleep. Traditional respiratory diagnostics involve basic laboratory tests, such as microscopy and biochemical tests. For tuberculosis case detection, microscopy continues to be an indispensable diagnostics tool, given its low cost, rapidity, simplicity of procedure, and high specificity.

Indication: Need for advanced respiratory diagnostic technologies to attain accurate testing of chronic obstructive pulmonary disease

Asthma is a chronic condition characterized by difficulty in breathing due to frequent, underlying inflammation of the airways. Respiratory diagnostic strategies for asthma usually involve pulmonary function tests, such as spirometry, which assess the extent of airway obstruction and reversibility. Moreover, the measurement of fractional exhaled nitric oxide (FeNO) indirectly reflects airway inflammation, providing further diagnostic insight. Chronic obstructive pulmonary disease (COPD) is a progressive lung disease that causes breathing difficulties and features chronic bronchitis and emphysema. Respiratory diagnostics for COPD involve a range of tests, including the spirometry test to measure lung function, a chest X-ray or CT scan to view the lungs, and arterial blood gas analysis to measure how well the lungs are transferring oxygen to the bloodstream and removing carbon dioxide. Lung cancer, a serious and potentially fatal disease, often originates in the cells lining the bronchi or bronchioles. Diagnosis typically includes imaging tests such as chest X-rays and CT scans for initial detection. Pneumonia is an infection that inflames the air sacs in one or both lungs. The disease is typically diagnosed through physical examinations, followed by a chest X-ray, which can confirm the infection and determine its location and extent. Additionally, sputum tests and blood tests can be utilized to identify the type of microorganism causing the infection, helping to determine the most effective treatment approach. Tuberculosis is a potentially severe infectious disease affecting primarily the lungs. Two main tests are used in respiratory diagnostics for TB: the skin test, which identifies TB exposure, and the interferon-gamma release assay, which can confirm active or latent infection. A chest X-ray or CT scan may be used to assess lung damage further, while a sputum test can reveal if the strain of TB is drug-resistant, assisting in treatment planning.

End-User: Adoption of a diverse range of diagnostic tools in hospitals and clinics for identifying and monitoring respiratory ailments

Diagnostic laboratories form a critical component of the end-use landscape for respiratory diagnostics. These entities are consistently involved in testing and diagnosis of various respiratory conditions such as chronic obstructive pulmonary disease (COPD), asthma, tuberculosis, and pneumonia. With their highly advanced and complex set of testing equipment, diagnostic laboratories offer accurate and reliable results, serving as a key milestone in the patient's journey toward appropriate treatment and recovery. Hospitals, given their primary role in healthcare delivery, are equipped with state-of-the-art respiratory diagnostics tools for identifying respiratory diseases. Their usage extends from outpatient departments to intensive care units, bringing precise and timely diagnostics to the broadest set of patients. Research institutes play an indispensable role in the field of respiratory diagnostics. These institutions are vital in both evaluating the efficacy of existing diagnostic tools and developing the next generation of respiratory diagnostic solutions. They facilitate extensive research into diagnostic methods that can identify diseases at an earlier stage to increase the survival rate and minimize the impact on patient's quality of life.

Regional Insights

The Americas pose a significant position in the global market for respiratory diagnostics. High incidences of respiratory diseases coupled with heightened awareness and proactive medical interventions contribute to the need for advanced respiratory diagnostics in the Americas. The availability of sophisticated healthcare infrastructure also facilitates the production of high-quality diagnostic equipment. The escalating demand for diagnostic services and the presence of rapidly developing healthcare infrastructure support the production of respiratory diagnostic devices in Asia. The prevalence of respiratory diseases and the expansion of key market players, both domestic and international,, have elevated market development in the region. Europe's market for respiratory diagnostics is heavily influenced by the high availability of innovative respiratory diagnostic tests and the presence of well-established healthcare systems. Regulatory guidelines laid down by the European Union also pave the way for stringent quality control during the production of respiratory diagnostic devices. Middle East & Africa also observes an increasing prevalence of respiratory diseases, creating a need for consistent availability of advanced diagnosis solutions. The production of respiratory diagnostic devices is limited in the region due to a lack of local manufacturers. However, various international companies are focusing on and have expanded their foothold in this region for respiratory diagnostic device manufacturing.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Respiratory Diagnostics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Respiratory Diagnostics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Respiratory Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Adaltis S.r.l., Altona Diagnostics GmbH, Becton, Dickinson, and Company, Bio-Rad Laboratories, Inc., bioMerieux S.A., Bioneer Corporation, CerTest Biotec S.L., Daan Gene Co., Ltd., Diatech Pharmacogenetics srl, Dragerwerk AG & Co. KGaA, F. Hoffmann-La Roche Ltd., GE HealthCare Technologies, Inc., Hologic, Inc., Johnson & Johnson Services, Inc., Koninklijke Philips N.V., Masimo Corporation, Medtronic PLC, Merck KGaA, ProAxsis by NetScientific PLC, Quest Diagnostics Incorporated, Quidel Corporation, Sansure Biotech Inc., SDI Diagnostics, Inc., Seegene Inc., Siemens Healthineers AG, Somnoware by ResMed Corp., Thermo Fisher Scientific Inc., Vitalograph Ltd., and ZeptoMetrix LLC.

Market Segmentation & Coverage

This research report categorizes the Respiratory Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Product
  • Assays & Reagents
  • Instruments & Devices
  • Software & Services

• Test Type
  • Imaging Tests
    • Computed Tomography
    • Magnetic Resonance Imaging
    • Positron Emission Tomography
    • X-Ray

• Mechanical Tests
  • Peak Flow Test
  • Pulmonary Function Tests
  • Spirometry

• Molecular Diagnostic Tests
  • DNA Sequencing & Next-Generation Sequencing
  • In Situ Hybridization
  • Microarrays
  • Nucleic Acid Amplification Test
  • PCR

• OSA Diagnostic Tests
• Traditional Diagnostic Tests
  • Biochemical Tests
  • Immunodiagnostics
  • Microscopy
• Indication
  • Asthma
  • Chronic Obstructive Pulmonary Disease
  • Lung Cancer
  • Pneumonia
  • Tuberculosis

• End-User
  • Diagnostic Laboratories
  • Hospitals & Clinics
  • Research Institutes

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Respiratory Diagnostics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Respiratory Diagnostics Market?

3. What are the technology trends and regulatory frameworks in the Respiratory Diagnostics Market?

4. What is the market share of the leading vendors in the Respiratory Diagnostics Market?

5. Which modes and strategic moves are suitable for entering the Respiratory Diagnostics Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing aging population with susceptibility to chronic respiratory diseases
    • 5.1.1.2. Growth in the approvals for respiratory disease diagnostic kits, tests, and systems
    • 5.1.1.3. Rising preferences for remote and home care testing devices
  • 5.1.2. Restraints
    • 5.1.2.1. Incidences of product recall of respiratory diagnosis panels and kits with limited reimbursement policies
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancements to introduce sophisticated respiratory diagnostic tools
    • 5.1.3.2. Government initiatives and funding for respiratory diagnostic tools
  • 5.1.4. Challenges
    • 5.1.4.1. Risk of errors associated with complex diagnostic procedures
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Need for rapid detection of pathogens driving the adoption of assays and reagents
  • 5.2.2. Test Type: Research initiatives to advance the accuracy and specificity of molecular diagnostic tests
  • 5.2.3. Indication: Need for advanced respiratory diagnostic technologies to attain accurate testing of chronic obstructive pulmonary disease
  • 5.2.4. End-User: Adoption of a diverse range of diagnostic tools in hospitals and clinics for identifying and monitoring respiratory ailments
• 5.3. Market Trend Analysis
  • 5.3.1. Significant market growth potential driven by investments in healthcare infrastructure and supportive regulatory landscape in the Americas region
  • 5.3.2. Massive need of early detection and respiratory diagnostic solutions to monitor and manage viral respiratory infections in APAC
  • 5.3.3. Well-established respiratory diagnostics development across EMEA enabling the provision of advanced testing capabilities for government and private disease screening activities
• 5.4. Cumulative Impact of High Inflation
• 5.5. Porter's Five Forces Analysis
  • 5.5.1. Threat of New Entrants
  • 5.5.2. Threat of Substitutes
  • 5.5.3. Bargaining Power of Customers
  • 5.5.4. Bargaining Power of Suppliers
  • 5.5.5. Industry Rivalry
• 5.6. Value Chain & Critical Path Analysis
• 5.7. Regulatory Framework Analysis

6. Respiratory Diagnostics Market, by Product

• 6.1. Introduction
• 6.2. Assays & Reagents
• 6.3. Instruments & Devices
• 6.4. Software & Services

7. Respiratory Diagnostics Market, by Test Type

• 7.1. Introduction
• 7.2. Imaging Tests
• 7.3. Mechanical Tests
• 7.4. Molecular Diagnostic Tests
• 7.5. OSA Diagnostic Tests
• 7.6. Traditional Diagnostic Tests

8. Respiratory Diagnostics Market, by Indication

• 8.1. Introduction
• 8.2. Asthma
• 8.3. Chronic Obstructive Pulmonary Disease
• 8.4. Lung Cancer
• 8.5. Pneumonia
• 8.6. Tuberculosis

9. Respiratory Diagnostics Market, by End-User

• 9.1. Introduction
• 9.2. Diagnostic Laboratories
• 9.3. Hospitals & Clinics
• 9.4. Research Institutes

10. Americas Respiratory Diagnostics Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Respiratory Diagnostics Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Respiratory Diagnostics Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. NYU Langone Health Enters 8-Year Partnership with Philips
  • 13.3.2. Masimo Gets De Novo Approval From FDA for ORi
  • 13.3.3. bioMerieux Submits Dual 510(k) and CLIA-Waiver Application to FDA for the BIOFIRE SPOTFIRE Respiratory/Sore Throat (R/ST) Panel
  • 13.3.4. BD Receives 510(k) Clearance for COVID-19, Influenza A/B, RSV Molecular Combination Test
  • 13.3.5. ResMed Acquires Sleep and Respiratory Diagnostics Software Maker Somnoware
  • 13.3.6. Seegene Obtains IVDR Certification for 30 Diagnostic Assays
  • 13.3.7. Hologic Announces FDA Clearance of Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay
  • 13.3.8. QIAGEN Launches QIAstat-Dx in Japan with Respiratory Panel for Syndromic Testing
  • 13.3.9. Thermo Fisher partners with ALPCO-GeneProof to Broaden Their CE-IVD Molecular Assay Portfolio
  • 13.3.10. Molbio Diagnostics adds Truenat H3N2/H1N1 Test to Respiratory Disease Portfolio
  • 13.3.11. Vitalograph Launches New Respiratory VitaloPFT Series
  • 13.3.12. SD Biosensor and SJL Partners Complete Transaction to Acquire Meridian Bioscience
  • 13.3.13. Philips and Masimo Expand Partnership To Improve Telehealth For Patients And Clinicians Around The World

14. Competitive Portfolio

• 14.1. Key Company Profiles
• 14.2. Key Product Portfolio